Skip to content
2000
Volume 13, Issue 12
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The Cytochrome P450 4 (CYP4) family of enzymes in humans is comprised of thirteen isozymes that typically catalyze the ω-oxidation of endogenous fatty acids and eicosanoids. Several CYP4 enzymes can biosynthesize 20- hydroxyeicosatetraenoic acid, or 20-HETE, an important signaling eicosanoid involved in regulation of vascular tone and kidney reabsorption. Additionally, accumulation of certain fatty acids is a hallmark of the rare genetic disorders, Refsum disease and X-ALD. Therefore, modulation of CYP4 enzyme activity, either by inhibition or induction, is a potential strategy for drug discovery. Here we review the substrate specificities, sites of expression, genetic regulation, and inhibition by exogenous chemicals of the human CYP4 enzymes, and discuss the targeting of CYP4 enzymes in the development of new treatments for hypertension, stroke, certain cancers and the fatty acid-linked orphan diseases.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/15680266113139990110
2013-06-01
2025-07-07
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/15680266113139990110
Loading

  • Article Type:
    Research Article
Keyword(s): 20-HETE; cancer; CYP4; HET0016; hypertension; Refsum disease; stroke; X-ALD
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test